AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$CRMD

CorMedix Inc.

Price · $CRMDvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $CRMD in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $CRMD in the last 30 days.

Top stories · $CRMDMore →
MAY 14·StocktwitsHigh

CRMD Stock Soared 18% Today – Here’s What Fueled CorMedix’s Triple-Digit Q1 Revenue Surge

CorMedix (CRMD) shares surged over 18% after the company reported strong first-quarter results, with revenue reaching $127.4 million, significantly exceeding Wall Street's expectations. The impressive growth was largely driven by DefenCath sales, prompting CorMedix to raise its full-year 2026 revenue and adjusted EBITDA guidance. Retail sentiment on Stocktwits also shifted to bullish following the positive news.

APR 1·Intellectia AI

CRMD Financials: Revenue Breakdown, Margins & Competitor Comparison

This article analyzes the financial performance of CorMedix Inc (CRMD), focusing on its revenue breakdown, profitability margins, and competitive positioning. CRMD boasts a gross margin of 83.43%, an operating margin of 45.97%, and a net margin of 10.90%, alongside a Return on Equity (ROE) of 66.56%. The article also compares CRMD's market capitalization of $536.75M and its gross margin against competitors CTNM and CMPS, for which gross margin data is N/A.

JAN 3·Finviz

INSM Stock Up 78% in 6 Months: Here's What You Need to Know

Insmed's stock has surged 78% in six months, largely due to the FDA approval of Brinsupri, its second marketed product, which generated $28.1 million in its first quarter. The company also benefits from steady sales of Arikayce and continues to advance its pipeline despite a recent setback in a phase IIb study. Several other biotech stocks like ANI Pharmaceuticals, CorMedix, and Castle Biosciences also show strong performance.

News on $CRMD